Patents by Inventor James C. Kauer

James C. Kauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 6693076
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: February 17, 2004
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino
  • Multicatalytic protease inhibitors
    Patent number: 5990083
    Abstract: Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: November 23, 1999
    Assignee: Cephalon, Inc.
    Inventors: Mohamed Iqbal, James L. Diebold, Robert Siman, Sankar Chatterjee, James C. Kauer
  • Multicatalytic protease inhibitors
    Patent number: 5830870
    Abstract: Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: November 3, 1998
    Assignee: Cephalon, Inc.
    Inventors: Mohamed Iqbal, James L. Diebold, Robert Siman, Sankar Chatterjee, James C. Kauer
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5776897
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: July 7, 1998
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5756494
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 26, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Protein kinase inhibitors for treatmen of neurological disorders
    Patent number: 5741808
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: April 21, 1998
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5703045
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • Treating disorders by application of insulin-like growth factors and analogs
    Patent number: 5652214
    Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method including the step of administering to the mammal one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
    Type: Grant
    Filed: October 7, 1992
    Date of Patent: July 29, 1997
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
  • K-252a derivatives for treatment of neurological disorders
    Patent number: 5621100
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Protein kinase inhibitors for treatment of neurological disorders
    Patent number: 5621101
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 15, 1997
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman, Fumihiko Kanai, Masami Kaneko
  • Multicatalytic protease inhibitors
    Patent number: 5614649
    Abstract: Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.
    Type: Grant
    Filed: November 3, 1995
    Date of Patent: March 25, 1997
    Assignee: Cephalon, Inc.
    Inventors: Mohamed Iqbal, James L. Diebold, Robert Siman, Sankar Chatterjee, James C. Kauer
  • Multicatalytic protease inhibitors
    Patent number: 5550262
    Abstract: Disclosed herein are inbibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: August 27, 1996
    Assignee: Cephalon, Inc.
    Inventors: Mohamed Iqbal, James L. Diebold, Robert Siman, Sankar Chatterjee, James C. Kauer
  • Selected protein kinase inhibitors for the treatment of neurological disorders
    Patent number: 5461146
    Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: October 24, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Michael E. Lewis, James C. Kauer, Nicola Neff, Jill Roberts-Lewis, Chikara Murakata, Hiromitsu Saito, Yuzuru Matsuda, Marcie A. Glicksman
  • Nerve growth factor peptides
    Patent number: 5134121
    Abstract: The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: July 28, 1992
    Assignee: Regents of the University of California
    Inventors: William C. Mobley, Frank M. Longo, James C. Kauer
  • Treating disorders by application of insulin-like growth factor
    Patent number: 5093317
    Abstract: Method of enhancing the survival of neuronal cells, more preferably non-mitotic neuronal cells and/or cholinergic cells in a mammal, which cells are at risk of dying, which method includes administering to the mammal an effective amount of a functional derivative of Insulin-like Growth Factor I or Insulin-like Growth Factor II.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: March 3, 1992
    Assignee: Cephalon, Inc.
    Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Jr.
  • Photoreactive benzoylphenylalanines and related peptides
    Patent number: 4762881
    Abstract: Provided is a benzoylphenylalanine of the formula: ##STR1## wherein ##STR2## is in the m or p position; and Pr is a protecting group which is easily cleavable in the presence of a peptide bond by a mild acid or base.This benzoylphenylalanine group is incorporated into a peptide chain which can be attached to a solid substrate having a reactive hydrogen by exposure to low energy ultraviolet light.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: August 9, 1988
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: James C. Kauer
  • Aralkylcarbamoyl peptide alcohols
    Patent number: 4511390
    Abstract: Aralkylcarbamoyl peptide alcohols of the formula ##STR1## selectively stimulate nitrate and ammonium ion uptake by plants.
    Type: Grant
    Filed: June 10, 1983
    Date of Patent: April 16, 1985
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: James C. Kauer